Evaxion Biotech A/S (NASDAQ:EVAX) Q1 2026 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Evaxion Business Update and First Quarter 2026 Financial Results Webcast and Conference Call.
Evaxion A/S (EVAX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Ikarian Capital Neil Shahrestani | 74,698 | $356,310 | -7% | 0.03% |
| 2. | Point72 Asset Management Steve Cohen | 33,100 | $157,887 | 0% | |
| 3. | Stonepine Capital Timothy P. Lynch | 20,000 | $95,400 | 0.07% |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 30,000 | $111,600 | 0.02% | |
| 2. | 13,808 | $51,366 | 0.02% | |
| 3. | 10,000 | $37,200 | 0% | |
| 4. | 8,000 | $29,760 | 0% | |
| 5. | 5,198 | $19,337 | 0% |
News See All
Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Evaxion Business Update and Full Year 2025 Financial Results Webcast and Conference Call. [Operator Instructions].
Evaxion Biotech A/S (NASDAQ:EVAX) Q3 2025 Earnings Call Transcript
Operator: Hello, and welcome to the Evaxion Business Update and Third Quarter 2025 Financial Results. [Operator Instructions] Please be advised that today's conference is being recorded.
Lake Street Raises Evaxion (EVAX) PT to $11 Following Positive Two-Year EVX-01 Melanoma Data
Evaxion (NASDAQ:EVAX) is one of the hot stocks to buy with huge upside potential.
12 Hot Stocks to Buy with Huge Upside Potential
On October 22, Vios Advisors’ Michael Bapis and BNY’s Alicia Levine joined CNBC's 'Closing Bell' to discuss the latest news affecting markets.
Evaxion Biotech A/S (NASDAQ:EVAX) Q2 2025 Earnings Call Transcript
Operator: Hello, and welcome to Evaxion's Second Quarter 2025 Conference Call. [Operator Instructions] I would now like to turn the conference over to Birgitte Rono, Interim CEO and CSO.
Evaxion Biotech Receives Grant Funding to Develop New Polio Vaccine
The funds will be used to support research into identifying and combining antigens to create a new vaccine design that does not utilize live viruses.
Evaxion Biotech A/S (NASDAQ:EVAX) Q1 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Evaxion First Quarter 2025 Conference Call and Webcast. At this time, all participants are in a listen-only mode.
Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Evaxion Biotech Business Update Full Year 2024 Conference Call and Webcast.
Evaxion Biotech A/S (NASDAQ:EVAX) Q2 2024 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Evaxion Biotech Business Update Conference call. [Operator Instructions] Please be advised, that today's conference is being recorded.
Hedge Fund Resource Center